National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Empagliflozin (Jardiance®). HTA ID: 21030

Empagliflozin (Jardiance®) is indicated for the treatment of symptomatic chronic heart failure with reduced ejection fraction.

 

NCPE Assessment Process Complete
Rapid review commissioned 05/07/2021
Rapid review completed 29/07/2021
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of empagliflozin compared with the current standard of care.